BofA keeps Buy on Sarepta, trims target after FDA pivots on SRP-9001 adcom
The Fly

BofA keeps Buy on Sarepta, trims target after FDA pivots on SRP-9001 adcom

BofA lowered the firm’s price target on Sarepta to $164 from $169 and keeps a Buy rating on the shares after the company announced that the FDA has changed its prior stance and now intends to hold an advisory committee meeting, or ad com, for SRP-9001. This "quick pivot gives us a bit of whiplash," but the firm had always assumed an ad com was likely and thinks Sarepta is "well-prepared," the analyst tells investors. The logistics of scheduling an ad com increases the burden on the agency for what is already a short review timeline, so the firm thinks the likelihood of a three month PDUFA extension is higher post the ad com for logistical reasons, though this does not change BofA’s view on the approvability of ‘9001.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SRPT:

Related Articles
TheFlySarepta management to meet with Cantor Fitzgerald
TipRanks Auto-Generated NewsdeskSarepta Therapeutics Expands Board, Welcomes New Director
TheFlyElection 2024: Where To Put Your Money Ahead of the Vote
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App